By Karuna Jaggar, Executive Director. A new study published on June 5,in the New England Journal of Medicine evaluated the efficacy of extending the treatment of letrozole from five to ten years for women with hormone positive breast cancer. Although the study found that there is a statistically significant reduction in recurrence of breast cancer in the same or the other breast, the study did not demonstrate improved overall survival for women with the longer course of treatment.
More research is needed to see how effective they are, who would most benefit from them, and how long treatment should be continued. Because of this, they are used mainly in women who are past menopause. AIs are used mainly to treat women with hormone receptor-positive breast cancer.
Aromatase inhibitors anastrozole, letrozole and exemestane are hormone therapy drugs used to treat hormone receptor-positive breast cancer. Aromatase inhibitors are only used to treat postmenopausal women and some premenopausal women also getting ovarian suppression. Some common side effects are described below.
In women, breast cancer is both the most common cancer worldwide and the second cause of cancer death Cardoso et al. ER expression and activation are important factors to control tumour growth and recurrence Chen In fact, AIs therapy presents higher clinical efficacy, prolonged disease-free survival and time to recurrence, and significantly less severe side effects than tamoxifen. Nevertheless, clinical trials generally suggest that AIs therapy does not significantly improve overall survival when compared to tamoxifen therapy Bonneterre et al.
Jump to navigation. Advanced or metastatic breast cancer is cancer that has spread beyond the breast and regional lymph node areas. Breast cancer can progress to metastatic disease despite the person undergoing a range of therapies given after initial treatment, such as surgery, chemotherapy or radiation therapy.
Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer.
In trials in which a comparator group received tamoxifen followed by an aromatase inhibitor, recurrence rates were lower with aromatase inhibitors during the period that treatment differed between groups. The meta-analyses included individual data on 31, postmenopausal women with estrogen receptor—positive early breast cancer in randomized trials of 5 years of an aromatase inhibitor vs 5 years of tamoxifen; 5 years of an aromatase inhibitor vs 2 to 3 years of tamoxifen then an aromatase inhibitor to year 5; and 2 to 3 years of tamoxifen then an aromatase inhibitor to year 5 vs 5 years of tamoxifen. Outcomes were analyzed on an intent-to-treat basis stratified by age, nodal status, and trial, yielding aromatase inhibitor vs tamoxifen first-event rate ratios RRs; P values are two-sided. Ten-year breast cancer mortality was
Aromatase inhibitors are a group of drugs used to treat breast cancer in women who have been through the menopause. Men with breast cancer may be given an aromatase inhibitor, although another drug called tamoxifen is more commonly used. All three aromatase inhibitor drugs have similar effects and no one drug is better than another.
Aromatase inhibitors stop the production of estrogen in postmenopausal women. This means that less estrogen is available to stimulate the growth of hormone-receptor-positive breast cancer cells. Aromatase inhibitors can't stop the ovaries from making estrogen, so aromatase inhibitors are mainly used to treat postmenopausal women.